Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.81 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.74 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.74 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828933 | 0.90 | MTOR (0.78) | MTORPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2154120 | 0.90 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL13828787 | 0.87 | MTOR (0.79) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL32393 | 0.85 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765097 | 0.85 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL16625649 | 0.83 | PIK3CA (0.69) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL3719933 | 0.83 | MTOR (0.69) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL18431430 | 0.83 | PIK3CA (0.69) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL16625872 | 0.83 | PIK3CA (0.69) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL13828887 | 0.83 | MTOR (0.63) | MTORPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CG 9/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CG 9/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.